olaparib,bevacizumab
astrazeneca,merck,roche
['ovarian', 'olaparib', 'paola1']
paola1 trial: 65.5% of patients with hrd+ ovarian cancer treated with olaparib+bev alive at 5 years vs 48.4% in bev. presented at #esmo2022 paris 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"